MX2023006176A - Nuevos derivados de indazol acetileno. - Google Patents

Nuevos derivados de indazol acetileno.

Info

Publication number
MX2023006176A
MX2023006176A MX2023006176A MX2023006176A MX2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A
Authority
MX
Mexico
Prior art keywords
sup
acetylene derivatives
new indazole
indazole
new
Prior art date
Application number
MX2023006176A
Other languages
English (en)
Inventor
Cosimo Dolente
Sander Ulrike Obst
Annick Goergler
Georg Jaeschke
Antonio Ricci
David Stephen Hewings
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023006176A publication Critical patent/MX2023006176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos novedosos que tienen la fórmula general (I) (ver Fórmula) (I) o una sal farmacéuticamente aceptable de estos, en donde R1, R2, R2', R3, R4 y R5 son como se describe en la presente. El compuesto de fórmula (I) puede usarse como un medicamento.
MX2023006176A 2020-12-01 2021-11-29 Nuevos derivados de indazol acetileno. MX2023006176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (1)

Publication Number Publication Date
MX2023006176A true MX2023006176A (es) 2023-06-08

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006176A MX2023006176A (es) 2020-12-01 2021-11-29 Nuevos derivados de indazol acetileno.

Country Status (16)

Country Link
US (1) US20240002390A1 (es)
EP (1) EP4255908A1 (es)
JP (1) JP2023550902A (es)
KR (1) KR20230116799A (es)
CN (1) CN116490182A (es)
AR (1) AR124170A1 (es)
AU (1) AU2021393722A1 (es)
CA (1) CA3197659A1 (es)
CL (1) CL2023001440A1 (es)
CO (1) CO2023006912A2 (es)
CR (1) CR20230218A (es)
IL (1) IL303064A (es)
MX (1) MX2023006176A (es)
PE (1) PE20240099A1 (es)
TW (1) TW202237611A (es)
WO (1) WO2022117477A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217924A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
CR20200625A (es) * 2018-06-29 2021-02-05 Hoffmann La Roche Compuestos

Also Published As

Publication number Publication date
CO2023006912A2 (es) 2023-06-09
TW202237611A (zh) 2022-10-01
CN116490182A (zh) 2023-07-25
AR124170A1 (es) 2023-02-22
EP4255908A1 (en) 2023-10-11
PE20240099A1 (es) 2024-01-18
JP2023550902A (ja) 2023-12-06
US20240002390A1 (en) 2024-01-04
WO2022117477A1 (en) 2022-06-09
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
CL2023001440A1 (es) 2023-12-01
AU2021393722A1 (en) 2023-04-13
KR20230116799A (ko) 2023-08-04
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2022015886A (es) Derivados de amidopirimidona.
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MX2022006470A (es) Tiromimeticos novedosos.
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
SE0200919D0 (sv) Chemical compounds
WO2003049690A3 (en) Hiv integrase inhibitors
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
CR20230218A (es) Nuevos derivados de indazol acetileno
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2022008487A (es) Degradadores de smarca2-vhl.
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.